• Careers
  • Investors
  • News
  • Partnering
  • Contact Us
 
  • Home
  • Our Products
    • Recent Products
    • Consumer Products
    • Medical Devices & Diagnostics
    • Prescription Products
    • Product Coupons
  • Our Caring
    • Our Stories
    • Our Giving
    • Our Responsibility
    • Protecting Our People
    • Company Initiatives
  • Our Company
    • Our Credo Values
    • Our Management Approach
    • Our Citizenship
    • Corporate Governance
    • Company Structure
    • Our People & Diversity
    • Company Publications
    • Our History
  • News
    • All News
    • Corporate News
    • Product And Operating Company News
    • Financial News
    • Media Contacts
    • All News Archive
  • Text Size
  • Text Only
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | .... 39 Next >
Healthy Vision & Contact Lenses – New Educational Resource Offers Important Advice on Safe Wear And Care Of Contact Lenses

September 05, 2012

Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline

August 31, 2012

Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia

August 30, 2012

Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab

August 30, 2012

U.S. FDA Grants Priority Review Of ZYTIGA® (Abiraterone Acetate) sNDA For Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy

August 29, 2012

FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

August 29, 2012

< Prev | | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Employees
  • Careers
  • Investors
  • News
  • Partnering
  • Contact Us
Johnson & Johnson
  • Home
  • Our Products
  • Our Caring
  • Our Company
  • All News
  • Corporate News
  • Product And Operating Company News
  • Financial News
  • Media Contacts
  • All News Archive
  • Text Size
  • Graphic Version
  • Email to a Friend
  • Printer Friendly
  • RSS

All News

Find press releases issued in the past two years issued by Johnson & Johnson corporate headquarters and our operating companies.

< Prev | | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | .... 39 Next >
Healthy Vision & Contact Lenses – New Educational Resource Offers Important Advice on Safe Wear And Care Of Contact Lenses

September 05, 2012

Janssen-Cilag International NV (Janssen) Submits European Marketing Authorisation Application for Investigational Multi-Drug Resistant Tuberculosis Treatment Bedaquiline

August 31, 2012

Janssen Pharmaceuticals, Inc. announces RISPERDAL® consumer protection settlement with 36 states and the District of Columbia

August 30, 2012

Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab

August 30, 2012

U.S. FDA Grants Priority Review Of ZYTIGA® (Abiraterone Acetate) sNDA For Treatment of Metastatic Castration-Resistant Prostate Cancer before Chemotherapy

August 29, 2012

FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

August 29, 2012

< Prev | | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | .... 39 Next >
  • Accessibility
  • Sitemap
  • Privacy Policy
  • Legal Notice
  • Employees
This site is governed solely by applicable U.S. laws and governmental regulations. Please see our Privacy Policy. Use of this site constitutes your consent to application of such laws and regulations and to our Privacy Policy. Your use of the information on this site is subject to the terms of our Legal Notice. You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact Us with any questions or search this site for more information.
All contents © Copyright Johnson & Johnson Services, Inc.1997-2013. All Rights Reserved.
  • Find us at
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •